Press Release: Statement of Total Voting Rights and Shares Forming The Company's Share Capital as of May 22, 2026

Dow Jones06-10

Article R. 22-10-23 of the French Commercial Code

Market : Euronext Paris

ISIN code / Mnemo: FR0013233012 / IVA

Web site: www.inventivapharma.com 

 
                Number of Shares    Total Voting Rights,  Total Voting Rights, 
Date               Outstanding            Gross (1)              Net (2) 
-------------  -------------------  --------------------  -------------------- 
May 22, 2026           209 007 475           218 082 368           218 082 368 
-------------  -------------------  --------------------  -------------------- 
 
   1. The total number of gross (or "theoretical") voting rights is used as the 
      basis for calculating threshold crossings. In accordance with Article 
      223-11 of the AMF General Regulations, this number is calculated on the 
      basis of all shares to which voting rights are attached, including those 
      for which voting rights have been suspended. 
   1. The total number of net (or "exercisable at a Shareholders' Meeting") 
      voting rights is calculated without taking into account shares for which 
      voting rights have been suspended, i.e. treasury shares (including shares 
      purchased under the liquidity contract). It is released in order to 
      ensure that the public is properly informed.

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). https://www.inventivapharma.com

Contacts 

 
Media Relations Pascaline Clerc:        Investor Relations David Nikodem: 
media@inventivapharma.com Mark Corbae:  IR@inventivapharma.com Patricia L. 
inventivapr@icrhealthcare.com           Bank: patti.bank@icrhealthcare.com

Attachment 

   -- Inventiva - PR - Voting Rights - EN - 06 09 2026

(END) Dow Jones Newswires

June 09, 2026 16:00 ET (20:00 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment